Paraneoplastic opsoclonus myoclonus syndrome in adults …

Neuro-Oncology

Updated 05.28.2024
Released 08.17.1995
Expires For CME 05.28.2027

Paraneoplastic opsoclonus myoclonus syndrome in adults

Authors: Shailee Shah MD MS, Shameer Rafee MRCPI

See Contributor Disclosures

Editor: Rimas V Lukas MD

Paraneoplastic opsoclonus myoclonus syndrome in adults

In This Article

Quick Link

Introduction

Overview

Opsoclonus myoclonus syndrome, colloquially known as a disease of “dancing feet and dancing eyes,” is a dramatic neurologic syndrome characterized by the presence of opsoclonus and frequently diffuse or focal myoclonus, truncal ataxia, encephalopathy, and brainstem or other cerebellar manifestations. The disorder is most frequently autoimmune, parainfectious, and paraneoplastic in both adults and children but has also been seen to occur in metabolic and lesional brain disorders, such as tumors or stroke. Opsoclonus myoclonus ataxia syndrome has been described post-SARS-CoV-2 in both adults and children with variable prognosis posttreatment with IVIG or steroids (21).

Opsoclonus myoclonus often occurs as a remote immunologically mediated effect of an otherwise occult neoplasm. Opsoclonus myoclonus syndrome is more common in children than adults. Neuroblastoma is the most common paraneoplastic driver of opsoclonus myoclonus syndrome in children, often without an underlying onconeural antibody identified (16). In adults, the most common malignancies are small cell lung cancer, breast adenocarcinoma, and ovarian teratoma. A cancer is identified in approximately 20% to 40% of cases, and onconeural antibodies are detected in only approximately 10% of patients. However, a subset of patients, often women, with antineuronal nuclear autoantibodies type 2 (ANNA2; anti-Ri) have demonstrated this phenotype in association with an underlying breast adenocarcinoma, small cell lung cancer, or ovarian tumor.

Some patients show significant neurologic improvement with successful tumor therapy or immunotherapy, whereas others are left with permanent and severe neurologic disability despite treatment. This article reviews the clinical features, autoimmune aspects, and practical patient management of paraneoplastic opsoclonus.

Key points

	• Most adults with opsoclonus myoclonus may have diffuse or incomplete manifestation of both symptoms and may additionally have truncal titubation, ataxia, and other cerebellar impairments.
	• Additional symptoms that can occur include brainstem dysfunction and encephalopathy, which can be associated with a poor prognosis.
	• Adults with paraneoplastic opsoclonus myoclonus syndrome most frequently have underlying small cell lung carcinoma or breast adenocarcinoma.
	• No one specific onconeural antibody is putative in the development of adult-onset paraneoplastic opsoclonus myoclonus, but instead several onconeural antibodies, most commonly ANNA2.
	• Outcomes in adults with paraneoplastic opsoclonus myoclonus are variable. Some patients improve dramatically with oncologic therapy and immunotherapy, whereas others are left with severe neurologic disability. Rapid detection and management may improve outcomes.

Historical note and terminology

The term "opsoclonus" was first used by Orzechowski in 1917 and later characterized as opsoclonus-myoclonus in 1927 in reference to chaotic, repetitive, rapid eye movements observed in several patients with nonepidemic encephalitis. At the bedside, opsoclonus is generally defined as involuntary, chaotic saccades in all planes (horizontal, vertical, torsional), worsened by attempts at voluntary saccades or fixation. In electro-oculographic recordings, opsoclonus is characterized by bursts of conjugate and dysconjugate saccadic oscillations without an intersaccadic interval. Opsoclonus occurs in association with numerous disorders in patients of all ages. Case reports of opsoclonus in adults with a variety of associated neoplasms date back more than 50 years. Paraneoplastic opsoclonus myoclonus is best described as syndromic and phenotypic description, rather than a unique disease, due to the number of heterogeneous neurologic diseases associated with the syndrome. As is common with paraneoplastic neurologic diseases, there is diversity in the neurologic presentations and underlying tumors seen with different autoantibodies.

Clinical manifestations

Presentation and course

Paraneoplastic opsoclonus myoclonus syndrome disease onset precedes the oncologic diagnosis. The onset of symptoms is usually acute over several weeks with rapid deterioration, may be fulminant, and is almost always dramatic.

The opsoclonus itself does not differ from the opsoclonus seen in association with a variety of nonneoplastic conditions. Patients with "ocular flutter" (defined as purely horizontal saccadic oscillations without an intersaccadic interval) are often included under the heading of opsoclonus. If the opsoclonus diminishes, it is often replaced by ocular flutter, dysmetric saccades, and nystagmus. Symptoms typically consist of vertigo and oscillopsia.

The other neurologic symptoms that accompany paraneoplastic opsoclonus myoclonus syndrome in adults are more heterogeneous (51; 01). Nearly all patients have spontaneous or stimulus-sensitive limb myoclonus. Myoclonus of the palate, face, larynx, or respiratory muscles may also occur. Encephalopathy is a common symptom in adult-onset opsoclonus myoclonus syndrome and accompanies other symptoms in about one quarter to two thirds of patients with paraneoplastic opsoclonus myoclonus syndrome (02). Pancerebellar dysfunction including limb, truncal, and gait ataxia, which varies in severity from mild to incapacitating, may occur, and patients may be left unable to stand or walk unaided. Signs and symptoms of brainstem dysfunction may also accompany the disease and include vertigo, vomiting, dysphagia, gaze palsy, jaw opening dystonia, and laryngospasm. Other patients develop additional signs and symptoms, some consistent with an encephalomyelitis (22). These presentations encompass varied combinations of encephalopathy, memory impairment, personality or behavioral disturbances, and corticospinal tract dysfunction.

Prognosis and complications

As a group, adults with paraneoplastic opsoclonus have a better neurologic outcome than patients with paraneoplastic cerebellar degeneration or encephalomyelitis. Spontaneous improvement of the opsoclonus and other neurologic features occasionally occurs (18; 47).

Clinical vignette

A 64-year-old woman was diagnosed with small cell lung carcinoma. She received six cycles of cisplatin and etoposide, followed by radiotherapy to the chest and prophylactic cranial irradiation. The treatment was completed within five months, and the patient attained a complete remission. Two months later she acutely developed vertigo, oscillopsia, intractable retching and vomiting, dysarthria, and severe gait instability. Over the next few weeks, she additionally developed emotional lability, confusion, short-term memory difficulties, and paresthesias of the hands and feet.

Initial neurologic examination showed opsoclonus, sometimes disconjugate, which worsened on attempted pursuit or saccade movements. There was myoclonic twitching of the eyelids and a coarse, rhythmic tremor of the lower face and tongue. She was moderately dysarthric with exaggerated gag reflex and jaw jerk. There was coarse polymyoclonus of all extremities, worsened with attempted rapid movements. Strength was normal in all limbs. Muscle stretch reflexes were absent. Babinski response was present bilaterally. There was moderate dysmetria and intention tremor of the upper extremities, and severe titubation of the head and trunk. Sensory testing showed a moderate decrease in vibratory sense from the knees distally, mildly impaired vibratory sense in the fingers, and relative preservation of proprioception. She was barely able to stand with assistance. Brain MR scan and spinal fluid were normal, and chest x-ray showed no tumor recurrence. Serum did not contain any identifiable antineuronal antibody reactivity.

The patient was begun on prednisone 80 mg/day and clonazepam 1 mg three times per day. Over the next three weeks the oscillopsia and vomiting significantly lessened. The opsoclonus disappeared, although attempted ocular pursuit movements were "choppy." Myoclonus was diminished, but she still had moderate limb, truncal, and gait ataxia and could not walk unaided. Over the subsequent month the prednisone dose was tapered and the opsoclonus did not return, but other symptoms remained stable. Further immunosuppressive therapy was being considered, but she died suddenly of a presumed pulmonary embolus three months after onset of neurologic symptoms.

Biological basis

Etiology and pathogenesis

Pathology. There are no distinctive or universally present neuropathologic abnormalities in paraneoplastic opsoclonus, nor does the severity of histologic changes at autopsy correlate with the degree of patients' neurologic impairment. Diffuse dropout of Purkinje cells was present in approximately one half of reported autopsied cases, ranging from mild to nearly complete (51; 06). Some cases with Purkinje cell loss also had perivascular mononuclear cell infiltrates in the cerebellum. Neuronal loss or perivascular mononuclear cell infiltrates in the brainstem, especially in the inferior olivary nuclei, may be present in addition to or instead of Purkinje cell loss (51; 01; 57; 06). In several reported autopsies of adults with paraneoplastic opsoclonus, there were no histopathologic abnormalities in either the cerebellum or brainstem (51).

It was previously believed that opsoclonus was primarily caused by dysfunction or loss of the "omnipause" neurons in the pontine reticular formation, but autopsy of the pons has not demonstrated these histologic changes (51). A separate hypothesis postulates that opsoclonus is the result of injury to Purkinje cells in the dorsal cerebellar vermis, leading to disinhibition of the fastigial cerebellar nuclei (59; 50). This is supported by cerebellar pathology in some (but not all) patients and by the report of two adults with opsoclonus in whom functional MR imaging showed abnormally high activation of deep cerebellar nuclei (27). The lack of consistent or universal pathologic lesions in patients with opsoclonus may imply that some patients have immune-mediated cerebellar neuronal dysfunction sufficient to cause clinical disease but short of causing neuronal cell death.

The proposed hypothesis underlying the development of paraneoplastic opsoclonus myoclonus syndrome is thought to be due to an aberrant autoantibody mediated humoral and cell-mediated immune response. There is thought to be cross-reactivity of immune cells targeting tumor cell antigens with neuronal tissue, resulting in an inflammatory response directed at neurons within the cerebellum and brainstem (11). It is probable that the exact nature of the immune dysfunction differs between subsets of patients. Inflammatory infiltrates in the brain or antineuronal antibodies in the serum of some patients with paraneoplastic opsoclonus indirectly support an autoimmune etiology, but the actual pathophysiologic mechanisms remain unknown.

The strongest evidence for an autoimmune pathogenesis of paraneoplastic opsoclonus is the presence in some patients of antineuronal autoantibodies in serum and CSF. Table 1 summarizes the autoantibodies associated with paraneoplastic opsoclonus in adults.

Table 1. Antineuronal Antibodies in Adults with Opsoclonus

Autoantibody	Tumor(s)	Cellular Location
Amphiphysin	Breast, small cell lung carcinoma	Intracellular (with transient expression on cell surface)
Anti-neuronal nuclear antibody type 1(ANNA1; anti-Hu)	Small cell lung carcinoma	Intracellular
Anti-neuronal nuclear antibody type 2 (ANNA2; anti-Ri)	Breast, ovarian, small cell lung carcinoma	Intracellular
Contactin-Associated Protein-like 2(CaspR2) IgG	Non-small cell lung carcinoma
Collapsin response-mediator protein 5 (CRMP5; CV2)	Small cell lung carcinoma, thymoma, others	Intracellular
Voltage gated calcium channel (VGCC)	Small cell lung carcinoma	Intracellular
Ma1/ Ma2 (Ta)	Germ cell tumors, others	Intracellular
Neuronal intermediate filament IgG	None: Anaplasma infection prior
N-methyl-D-aspartate receptor (NMDA-R)	Ovarian teratoma	Cell surface
Purkinje cell cytoplasmic antibody type 1 (PCA1; anti-Yo)	Breast, ovarian	Intracellular
Glutamic acid decarboxylase (GAD) 65	Thymoma (rarely)	Intracellular
GABA-B	Small cell lung cancer	Cell Surface
GABA-A	Thymoma	Cell Surface
Kelch-like (KLHL) protein 11 (KLHL11)	Ovarian cancer (reported in half of published papers)	Intracellular
Anti-SOX-1	Small cell lung cancer
Zic4	Small cell lung carcinoma	Unknown

ANNA2 was initially described in association with paraneoplastic opsoclonus myoclonus syndrome in women with breast or ovarian carcinoma (39). Reports show that the clinical syndromes and the tumors associated with ANNA2 are heterogeneous (47). ANNA2 antibodies can also be associated with small cell lung cancers but have also been found in non-small cell lung adenocarcinoma, and less commonly with other tumors (47). Most patients with paraneoplastic opsoclonus myoclonus syndrome and ANNA2 antibodies have limb and gait ataxia and brainstem dysfunction as well. However, ANNA2 antibodies are not specific to opsoclonus myoclonus syndrome. Some patients with ANNA2 antibodies have features of multifocal encephalomyelitis or brainstem encephalitis, but not opsoclonus (20). A retrospective review demonstrated opsoclonus with or without myoclonus in 28% of patients, and opsoclonus rarely appeared in isolation (55).

ANNA2-IgG stains the nuclei of neurons, with some tissue immunofluorescence cytoplasmic staining (39; 47). In contrast to ANNA1, ANNA2 does not react with the neurons of the dorsal root ganglia, sympathetic ganglia, or myenteric plexus (23). ANNA2 antibodies are thought to be directed against two 55 and 80kDa onconeural antigens, NOVA-1 and NOVA-2 (07; 60). The Nova proteins share sequence homology with a group of nuclear RNA-binding proteins believed to be involved in the regulation of mRNA splicing (30). This family of proteins is distinct from the RNA-binding proteins that react with ANNA1 antibodies. The Nova-1 and Nova-2 genes are differentially expressed by various subgroups of CNS neurons and are also expressed by gynecologic and lung tumors (07; 60).

As with other antineuronal antibodies associated with neurologic paraneoplastic syndromes, the role of intracellular onconeural antibodies remains unknown. Antibodies like ANNA2 likely represent an epiphenomenon or marker of primarily T-cell-mediated inflammation (47). A large proportion of patients with paraneoplastic opsoclonus myoclonus syndrome have no identifiable antineuronal antibodies (04; 52; 03).

Patients with paraneoplastic opsoclonus myoclonus syndrome may have antineuronal antibodies other than ANNA2 antibodies (Table 1). Several reported patients with opsoclonus, breast cancer, and diffuse cerebellar degeneration have PCA1 (anti-Yo) antibodies (45). Patients with small cell lung carcinoma or neuroblastoma, in whom opsoclonus is a component of multifocal paraneoplastic encephalomyelitis, may have ANNA1 antibodies that react with a group of 35 to 40 kd neuronal RNA-binding proteins. There are individual reports of patients with paraneoplastic opsoclonus and other antineuronal antibodies such as anti-Ma1 or anti-Ma2 antibodies and underlying tumors, particularly testicular germ cell (28), amphiphysin antibodies associated with breast or small cell lung carcinoma (48; 53; 57), CRMP5 antibodies associated with small cell lung cancer or thymoma (61), voltage-gated calcium channel antibodies associated with small cell lung cancer (32), anti-HNK1 antibodies associated with small cell lung cancer (02), and unclassified patterns of reactivity associated with small cell lung cancer or other neoplasms (09; 05). Opsoclonus myoclonus syndrome has been reported in patients with antibodies in which an association with malignancy is less frequent or where no underlying malignancy is identified, including against glutamic acid decarboxylase (GAD)65 (54). There are several reports of opsoclonus myoclonus syndrome associated with antibodies to NMDA-R with and without ovarian teratoma, GABAA receptors (46), or GABAB receptors (12). An initial paper describing a novel autoantibody KLHL11 did not describe opsoclonus myoclonus as an associated phenotype, but opsoclonus myoclonus syndrome in the presence of KLHL11 antibodies and ovarian teratoma has subsequently been reported (41; 42); further investigations are necessary to clarify this discrepancy.

An important note must be made regarding the recent use of immune-checkpoint inhibitors therapies for the management of several malignancies. A range of autoimmune disorders have occurred in the context of these medications, many of which with autoantibodies. Several cases have been reported, including one with ipilimumab/nivolumab opsoclonus myoclonus syndrome in a patient with malignant pleural mesothelioma that started 10 weeks after oncologic therapy was initiated (40).

As with children, nonparaneoplastic opsoclonus in adults frequently occurs after a respiratory or gastrointestinal illness. Patients develop acute to subacute onset opsoclonus, with myoclonus and ataxia. The syndrome is monophasic, and most patients make a good recovery within several weeks. Patients tend to be younger than their paraneoplastic counterparts (04). Parainfectious opsoclonus myoclonus syndrome is associated with several infections, including St. Louis encephalitis, Japanese encephalitis, herpes simplex, West Nile virus encephalitis (35), Epstein-Barr virus encephalitis, cytomegalovirus encephalitis, human herpesvirus 6 encephalitis, Powassen infection, and CNS Lyme disease. Persons with HIV infection may develop opsoclonus myoclonus syndrome in the seroconversion phase or during immune reconstitution after starting antiretroviral therapy or as a manifestation of CNS escape (24; 08). Opsoclonus myoclonus syndrome has been associated with diseases such as malaria, dengue, scrub-typhus, and chikungunya (14; 49; 38). A single case of post vaccination opsoclonus myoclonus syndrome has been reported after antirubella vaccination (37).

Opsoclonus myoclonus, among other movement disorders, has been reported post Sars-CoV-2 infection (19).

Opsoclonus may rarely occur in patients with structural lesions of the thalamus or upper midbrain, hemorrhage (34), neoplasms, and even sarcoidosis. Neurovascular compression in the brainstem has also been reported (44). Opsoclonus has been reported in patients with toxic or metabolic encephalopathies, including hyperosmolar nonketotic coma, organophosphate toxicity, amitriptyline overdose, cyclosporine toxicity, intravenous phenytoin, diazepam, as well as severe uremia (10; 25).

Diagnostic workup

Workup for adults with opsoclonus myoclonus syndrome includes MR of the brain with contrast, lumbar puncture (including oligoclonal bands and IgG index), and assays for serum and cerebrospinal antineuronal antibodies as detection in cerebrospinal fluid versus serum is different depending on antibody specificity.

CSF from most adults with paraneoplastic opsoclonus may contain one or more of the following abnormalities: (1) mildly elevated protein, (2) mild lymphocytic pleocytosis, (3) oligoclonal IgG bands, and (4) an elevated IgG index (51; 01; 36; 02). Brain MR scans are usually normal but occasionally show small, nonspecific lesions in the brainstem (39; 04).

Abnormalities in CSF (pleocytosis, protein elevations, oligoclonal bands, elevated IgG index) raises suspicion for a paraneoplastic disorder. However, this is far from reliable, as CSF abnormalities are common in patients with alternative causes of encephalitis, and conversely patients with paraneoplastic opsoclonus myoclonus syndrome may have normal CSF. The presence of high-titer antineuronal antibodies in the serum or CSF of an adult with opsoclonus is suggestive of the presence of an underlying tumor for which a malignancy workup should be pursued, but cases without identified underlying malignancy do occur, as has been seen with ANNA2 (39; 17; 29). ANNA2 antibodies may be detected in a small percentage of neurologically normal ovarian carcinoma patients (15). Patients with paraneoplastic opsoclonus myoclonus syndrome associated with small cell lung carcinoma or other tumors may have no detectable antineuronal antibodies or still unclassified antibodies.

As such, in patients older than 50 with opsoclonus myoclonus syndrome, there should be a high suspicion for an underlying malignancy, and rigorous testing should be pursued. Oncologic evaluation often consists of CT or PET (43). Testicular ultrasound in men and mammograms in women can be considered. When ANNA2 or PCA1 antibodies are present in women, mammography, pelvic examination, imaging of the pelvis, and measurement of serum carcinoembryonic antigen and CA 125 antigen levels can be pursued. Initial evaluation for an occult lung, breast, or other tumor may be unrevealing; in these patients the workup should be repeated at regular intervals (56). Age-appropriate cancer screening should not be neglected.

Management

The majority of patients with opsoclonus myoclonus syndrome and ANNA2 antibodies showed significant improvement following oncologic management or immunotherapy (39; 31; 47; 55). Patients with opsoclonus and breast or lung carcinoma, but no antineuronal antibodies, may also benefit from corticosteroids or combined treatment with steroids and intravenous immunoglobulin. Other treatment strategies include rituximab, cyclophosphamide, and intravenous immunoglobulin where clinical responses have been noted. Use of benzodiazepines and antiepileptics has also been reported, but no clear consensus exists on their role.

Overall treatment approach should be targeted at both the immunologic response and the underlying oncologic disease. If a tumor is identified and pathologically confirmed, immediate referral to an oncologist is necessary for appropriate oncologic management. Immunotherapy with intravenous methylprednisolone and intravenous immunoglobulin as first-line therapy should be considered, and in some cases with protracted, severe, or relapsing disease, second-line immunotherapeutic options with agents like cyclophosphamide can be considered.

Outcomes

Patients with underlying cancers and with delays in tumor diagnosis and treatment likely have a poorer prognosis (04). Patients may have significant and sometimes dramatic neurologic improvement with successful treatment of the associated lung cancer (01; 26), breast carcinoma (09), ovarian cancer (31), ovarian teratoma (03), renal carcinoma (13), or Hodgkin lymphoma (33). Some patients may improve spontaneously without treatment (04); however, most require and are recommended to obtain immunotherapy. Neurologic improvement following immunosuppressive treatment such as corticosteroids or plasmapheresis can be seen (04). Occasionally, the opsoclonus and other neurologic signs improve and worsen in association with regression and recurrence of the associated tumor (01; 04).

Unfortunately, some patients have suffered progressive encephalopathy leading to coma and death despite tumor treatment, corticosteroids, or plasmapheresis (51; 01; 04).

References

01: Anderson NE, Budde-Steffen C, Rosenblum MK, et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine 1988;67:100-9.** PMID 3352511
02: Armangue T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 2016;73(4):417-24. PMID 26856612
03: Armangue T, Titulaer J, Sabater L, et al. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol 2014;75(3):435-41. PMID 23613036
04: Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001;124:437-43.** PMID 24565194
05: Bataller L, Rosenfeld MR, Graus F, et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003;53:347-53.** PMID 12601702
06: Brievia-Ruiz L, Diaz-Hurtado M, Matias-Guiu X, Marquez-Medina D, Tarragona J, Graus F. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study. Clin Neurol Neurosurg 2008;110(10):1044-6. PMID 18701208
07: Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 1996;16:1114-22. PMID 8558240
08: Cabaraux P, Poncelet A, Honnorat J, Demeester R, Cherifi S, Manto M. CSF HIV RNA escape in opsoclonus-myoclonus-ataxia syndrome: case report and review of the literature. Front Neurol 2020;11:585527. PMID 33329331
09: Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord 1995;10:22-7. PMID 7885352
10: Changa AR, Rucker JC, Drummond PS. Opsoclonus in uremia with resolution after hemodialysis. J Neuroophthalmol 2022;42(1):e448-9. PMID 34270515
11: Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7(4):327-40.** PMID 18339348
12: DeFelipe-Mimbrera A, Masjuan J, Corral I, Villar LM, Graus F, Garcia-Barragan N. Opsoclonus-myoclonus syndrome and limbic encephalitis associated with GABAB receptor antibodies in CSF. J Neuroimmunol 2014;272(1-2):91-3. PMID 24814391
13: De Luca S, Terrone C, Crivellaro S, et al. Opsoclonus-myoclonus syndrome as a paraneoplastic manifestation of renal cell carcinoma. A case report and review of the literature. Urol Int 2002;68(3):206-8. PMID 11919472
14: do Rosario MS, Giovanetti M, de Jesus PAP, et al. Opsoclonus-myoclonus-ataxia syndrome associated with chikungunya and dengue virus co-infection. Int J Infect Dis 2018;75:11-4. PMID 30076990
15: Drlicek M, Bianchi G, Boglium G, et al. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 1997;244:85-9. PMID 9120501
16: Dropcho EJ. Remote neurologic manifestations of cancer. Neurol Clin 2002;20(1):85-122. PMID 11754303
17: Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993;43:207-11. PMID 8423887
18: Dropcho EJ, Payne R. Paraneoplastic opsoclonus-myoclonus: association with medullary thyroid carcinoma and review of the literature. Arch Neurol 1986;43:410-5. PMID 3954625
19: Emamikhah M, Babadi M, Mehrabani M, et al. Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. J Neurovirol 2021;27(1):26-34. PMID 33492608
20: Escudero D, Barnadas A, Codina M, Fueyo J, Graus F. Anti-Ri-associated paraneoplastic neurologic disorder without opsoclonus in a patient with breast cancer. Neurology 1993;43:1605-6. PMID 8351021
21: Finsterer J, Scorza FA. Opsoclonus myoclonus ataxia syndrome due to SARS-CoV-2. Neuroophthalmology 2022;47(1):1-6. PMID 36798867
22: Graus F, Ariño H, Dalmau J. Opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies-reply. JAMA Neurol 2016;73(7):891. PMID 27159281
23: Graus F, Rowe G, Fueyo J, Darnell RB, Dalmau J. The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. Neurosci Lett 1993;150:212-4. PMID 8469424
24: Guedes BF, Vieira Filho MAA, Listik C, et al. HIV-associated opsoclonus-myoclonus-ataxia syndrome: early infection, immune reconstitution syndrome or secondary to other diseases? Case report and literature review. J Neurovirol 2018;24(1):123-7. PMID 29243132
25: Haridas A, Ravi P. Opsoclonus-myoclonus syndrome caused by organophosphate poisoning. Pract Neurol 2023;23(3):243-5. PMID 36609395
26: Hassan KA, Kalemkerian GP, Trobe JD. Long-term survival in paraneoplastic opsoclonus-myoclonus syndrome associated with small cell lung cancer. J Neuroophthalmol 2008;28(1):27-30. PMID 18347455
27: Helmchen C, Rambold H, Sprenger A, Erdmann C, Binkofski F; fMRI study. Cerebellar activation in opsoclonus: an fMRI study. Neurology 2003;61:412-5. PMID 12913213
28: Hoffmann LA, Jarius S, Pellkofer HL, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008;79(7):767-73. PMID 18223018
29: Hormigo A, Dlamau J, Rosenblum MK, River ME, Posner JB. Immunological and pathological study of anti-Ri-associated encephalopathy. Ann Neurol 1994;36:896-902. PMID 7998777
30: Jensen KB, Dredge BK, Stefani G, et al. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron 2000;25:359-71. PMID 10719891
31: Jongen JL, Moll WJ, Sillevis Smitt PA, Vecht CJ, Tijssen CC. Anti-Ri positive opsoclonus-myoclonus-ataxia in ovarian duct cancer. J Neurol 1998;245:691-2. PMID 9776472
32: Josephson CB, Grant I, Benstead T. Opsoclonus-myoclonus with multiple paraneoplastic syndromes and VGCC antibodies. Can J Neurol Sci 2009;36(4):512-4. PMID 19650369
33: Kay CL, Davies-Jones GA, Singal R, Winfield DA. Paraneoplastic opsoclonus-myoclonus in Hodgkin's disease. J Neurol Neurosurg Psychiatry 1993;56:831-2. PMID 8331365
34: Keane JR, Devereaux MW. Opsoclonus associated with an intracranial tumor. Arch Ophthalmol 1974;92:443-5. PMID 4372975
35: Khosla JS, Edelman MJ, Kennedy N, Reich SG. West Nile virus presenting as opsoclonus-myoclonus cerebellar ataxia. Neurology 2005;64:1095. PMID 15781844
36: Klaas JP, Ahlskog JE, Pittock SJ, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol 2012;69(12):1598-607. PMID 22986354
37: Lapenna F, Lochi L, de Mari M, Iliceto G, Lamberti P. Post-vaccinic opsoclonus-myoclonus syndrome: a case report. Parkinsonism Relat Disord 2000;6(4):241-2. PMID 10900400
38: Lev D, Yahalom G, Rabinowicz S, Leshem E, Schwartz E. Opsoclonus-myoclonus as a presentation of post-malaria neurological syndrome. J Travel Med 2020;27(4):taaa051. PMID 32299096
39: Luque A, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991;29:241-51. PMID 2042940
40: Maller B, Peguero E, Tanvetyanon T. Ipilimumab/nivolumab-related opsoclonus-myoclonus-ataxia syndrome variant in a patient with malignant pleural mesothelioma. J Immunother 2018;41(9):411-2. PMID 29742520
41: Mandel-Brehm C, Dubey D, Kryzer TJ, et al. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med 2019;381(1):47-54. PMID 31269365
42: Maudes E, Landa J, Muñoz-Lopetegi A, et al. Clinical significance of Kelch-like protein 11 antibodies. Neurol Neuroimmunol Neuroinflamm 2020;7(3):e666. PMID 31953318
43: McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders. Arch Neurol 2010;67:322-9. PMID 20065123
44: Morinaga Y, Nii K, Sakamoto K, Inoue R, Mitsutake T, Hanada H. Neurovascular compression syndrome of the brain stem with opsoclonus-myoclonus syndrome combined with vestibular paroxysmia and autonomic symptoms. Drug Discov Ther 2019;13(4):228-31. PMID 31534075
45: Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration: a clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42:1931-7. PMID 1407575
46: Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13(3):276-86. PMID 24462240
47: Pittock SJ, Lucchinetti CF, Lennon VA. Anti-Neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003;53:580-7.** PMID 12730991
48: Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005;58(1):96-107. PMID 15984030
49: Ralph R, Prabhakar AT, Sathyendra S, Carey R, Jude J, Varghese GM. Scrub typhus-associated opsoclonus: clinical course and longitudinal outcomes in an Indian cohort. Ann Indian Acad Neurol 2019;22(2):153-8. PMID 31007425
50: Ramat S, Leigh J, Zee DS, Optican LM. What clinical disorders tell us about the neural control of saccadic eye movements. Brain 2007;130:10-35. PMID 17121745
51: Ridley A, Kennard C, Scholtz CL, et al. Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain 1987;110:1699-709. PMID 2827840
52: Sabater L, Xifro X, Saiz A, Alberch J, Graus F. Analysis of antibodies to neuronal surface antigens in adult opsoclonus-myoclonus. J Neuroimmunol 2008;196(1-2):188-91. PMID 18462809
53: Saiz A, Dalmau J, Butler MH, et al. Anti-amphiphysin I antibodies in patients with paraneoplastic neurologic disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 1999;66:214-7. PMID 10071102
54: Shaikh AG, Wilmot G. Opsoclonus in a patient with increased titers of anti-GAD antibody provides proof for the conductance-based model of saccadic oscillations. J Neurol Sci 2016;362:169-73. PMID 26944142
55: Simard C, Vogrig A, Joubert B, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm 2020;7(3):e699. PMID 32170042
56: Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumors in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18:19-27. PMID 20880069
57: Wessig C, Klein R, Schneider MF, et al. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003;61:195-8. PMID 12874398
58: Wirtz PW, Sillevis Smitt PA, Hoff JI, et al. Anti-Ri antibody positive opsoclonus-myoclonus in a male patient with breast carcinoma. J Neurol 2002;249:1710-2. PMID 12529794
59: Wong AM, Musallam S, Tomlinson RD, Shannon P, Sharpe JA. Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci 2001;189:71-81. PMID 11535236
60: Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci U S A 1998;95:13254-9. PMID 9789075
61: Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-54. PMID 11220734

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Shailee Shah MD MS

Dr. Shah of Vanderbilt University Medical Center has no relevant financial relationship to disclose.
See Profile
Shameer Rafee MRCPI

Dr. Rafee of University College Dublin received speaker's honorariums from Ipsen and Merz and travel grants from Abbvie and Ipsen.
See Profile

Editor

Rimas V Lukas MD

Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from Novartis and Novocure for speaking engagements, honorariums from Cardinal Health, Novocure, and Merck for advisory board membership, and research support from BMS as principal investigator.
See Profile

Former Authors

Edward J Dropcho MD
Daniel Lachance MD

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: Female>male, slightly greater than >1:1
Heredity: None
Population groups selectively affected: None
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Paraneoplastic opsoclonus myoclonus syndrome in adults

Associated Disorders

Breast carcinoma
Neuroblastoma
Paraneoplastic cerebellar degeneration
Paraneoplastic encephalomyelitis
Paraneoplastic extrapyramidal syndromes
- Small cell lung cancer
- Subacute brainstem encephalitis
- Tobacco abuse

Differential Diagnosis

nonparaneoplastic opsoclonus
benign encephalitis
acute opsoclonus
structural lesions of the thalamus
structural lesions of the brainstem
- toxic encephalopathies
- metabolic encephalopathies
- parainfectious encephalitis
- West Nile virus encephalitis
- HIV seroconversion

Paraneoplastic opsoclonus myoclonus syndrome in adults …

Paraneoplastic opsoclonus myoclonus syndrome in adults

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Antineuronal Antibodies in Adults with Opsoclonus

Epidemiology

Prevention

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

Paraneoplastic syndromes

Overview of neuropathology updates for infiltrating gliomas

Anti-IgLON5 disease

Anti-LGI1 encephalitis

Progressive encephalomyelitis with rigidity and myoclonus and glycine receptor antibodies

Paraneoplastic opsoclonus myoclonus syndrome in adults

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Antineuronal Antibodies in Adults with Opsoclonus

Epidemiology

Prevention

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

Paraneoplastic syndromes

Overview of neuropathology updates for infiltrating gliomas

Anti-IgLON5 disease

Anti-LGI1 encephalitis

Progressive encephalomyelitis with rigidity and myoclonus and glycine receptor antibodies

This is an article preview.
Start a Free Account
to access the full version.